<DOC>
	<DOCNO>NCT02755857</DOCNO>
	<brief_summary>This open-labelled , single arm study follow-on Study MPG010 compare relative bioavailability Lozanoc 65 mg Capsules Lozanoc 50 mg Capsules Sporanox 100 mg Capsules patient require itraconazole anti-fungal prophylaxis .</brief_summary>
	<brief_title>Bioavailability Study Lozanocâ„¢ 65 mg Itraconazole Capsules Patients Requiring Prophylaxis</brief_title>
	<detailed_description>After confirmation eligibility , participant take last dose current itraconazole therapy ( Lozanoc 50mg capsule Sporanox 100mg capsule ) morning Day 1 , commence therapy Lozanoc 65 mg capsule 21 day even Day 1 . The number Lozanoc 65mg capsule take participant 2 capsule ( 130mg ) morning evening OR number Lozanoc 50mg capsule participant receive study MPG010 , applicable . That , participant receive 3 x 50mg Lozanoc capsule morning evening study MPG010 he/she receive 3 x 65 mg Lozanoc 65 mg capsule , morning evening study MPG011 The dose study drug ( Lozanoc 65mg ) may dose-reduced ceased toxicity discretion investigator . Participants undergo follow assessment course study : - Concurrent medication ( ) - Clinical adverse event - Measurement vital sign ( weight , blood pressure , temperature ) - Targeted physical examination - Documentation evidence systemic fungal infection - Medication meal diary - 12-lead electrocardiogram ( ECG ) - Laboratory safety assessment - Renal function electrolyte ( urea , creatinine , estimate glomerular filtration rate [ eGFR ] , sodium , potassium , chlorine , bicarbonate ) - Liver function test ( bilirubin , albumin , total protein , alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) - Pharmacokinetic test - pre-morning dose ( 0 h sample ) Baseline ( Day 1 ) , Days 8 , 15 , 22 - 2 , 3.5 6 hour post morning dose Baseline ( Day 1 ) Day 22</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Provision write , inform consent Age least 18 year No clinical evidence active systemic fungal infection Physicianrecommended continuation oral itraconazole primary prophylaxis patient risk systemic fungal infection otherwise require longterm itraconazole maintenance regimen , include patient : heart , lung bone marrow transplant combination chemotherapy cancer aspergilloma , chronic pulmonary aspergillus bronchitis , allergic bronchopulmonary aspergillosis At least 21 day prior dose oral itraconazole , either Lozanoc 50mg capsule twice daily Sporanox 100mg capsule twice daily . Body mass index 15.0 35.0 kg/m2 Pregnant , plan pregnancy breastfeed Plasma itraconazole concentration great 1500ng/mL ( patient Lozanoc 50mg capsule ) Congestive cardiac failure cause ventricular dysfunction may outweigh benefit itraconazole Hypersensitivity Lozanoc excipients Coadministration follow drug : CYP3A4 metabolise substrate prolong QTinterval : sertindole , terfenadine CYP3A4 metabolise 3hydroxy3methylglutarylcoenzyme A ( HMGCoA ) reductase inhibitor : simvastatin , lovastatin Potent CYP3A4 inhibitor : dronedarone Triazolam , alprazolam oral midazolam Ergot alkaloid dihydroergotamine , ergometrine ( ergonovine ) ergotamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prophylaxis</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>